Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Blood (2024) 144 (Supplement 1): 779.

https://doi.org/10.1182/blood-2024-207557

Published: 2024

Journal Articles

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Jessica Kaplan Altman, Zhuoxin Sun, Alexander E. Perl, Richard Little, Steven D. Gore, Laura C. Michaelis, Geoffrey L. Uy, Yasmin Abaza, Sameem Abedin, John L. Reagan, Ehab L. Atallah, Selina Luger, Mark R. Litzow

Blood (2024) 144 (Supplement 1): 2907.1.

https://doi.org/10.1182/blood-2024-199701

Published: 2024

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Blood (2024) 144 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2024-207143

Published: 2024

Journal Articles

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

Blood (2023) 142 (Supplement 1): 594.

https://doi.org/10.1182/blood-2023-189734

Published: 2023

Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Blood (2023) 142 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2023-189648

Published: 2023

Journal Articles

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

Blood (2023) 142 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2023-179569

Published: 2023

Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Blood (2022) 140 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2022-171751

Published: 2022

Journal Articles

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

Yishai Ofran, Zhuoxin Sun, Jacob M. Rowe, David F. Claxton, Martin S. Tallman, Daniel A. Arber, Ari Melnick, Ross L. Levine, Elisabeth Paietta, John E. Godwin, Hillard M Lazarus, Selina M. Luger, James M. Foran, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 413.

https://doi.org/10.1182/blood-2021-149356

Published: 2021

Journal Articles

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Chezi Ganzel, Kevin Roopcharan, Zhuoxin Sun, Jacob M. Rowe, Hugo F Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M Lazarus, Larry D Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 690.

https://doi.org/10.1182/blood-2021-149208

Published: 2021

Journal Articles

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134211

Published: 2020

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health

Alan F. List, MD, Zhuoxin Sun, PhD, Amit Verma, MBBS, John M. Bennett, MD, Kathy McGraw, PhD, Jaroslaw P. Maciejewski, MD PhD, Rami S. Komrokji, MD, Timothy R. Wassenaar, MD, Selina M. Luger, MD FRCPC, Ryan J. Mattison, MD, Puneet S. Cheema, MD, Jessica K. Altman, David F. Claxton, MD, Charles A. Schiffer, MD, Andrew S. Artz, MD, Mark Litzow, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 842.

https://doi.org/10.1182/blood-2019-127274

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

Blood (2018) 132 (Supplement 1): 437.

https://doi.org/10.1182/blood-2018-99-113950

Published: 2018

Journal Articles

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

James M. Foran, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MD, John Godwin, MD, Yanming Zhang, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Keith W. Pratz, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2018-99-117838

Published: 2018

Journal Articles

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Jun Yin, PhD, Geoffrey L. Uy, MD, Betsy Laplant, MS, Elizabeth Storrick, Guido Marcucci, Hugo F. Fernandez, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD

Blood (2018) 132 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2018-99-113902

Published: 2018

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Blood (2018) 132 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2018-99-118383

Published: 2018

Journal Articles

Genomic Landscapes in Elderly AML

Blood (2017) 130 (Supplement 1): 404.

https://doi.org/10.1182/blood.V130.Suppl_1.404.404

Published: 2017

Journal Articles

Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial

Blood (2016) 128 (22): 339.

https://doi.org/10.1182/blood.V128.22.339.339

Published: 2016

NARROW

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Genomic Landscapes in Elderly AML

Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only